AstraZeneca Signs an Agreement with Catalent to Manufacture AZD1222 for COVID-19

 AstraZeneca Signs an Agreement with Catalent to Manufacture AZD1222 for COVID-19

AstraZeneca Signs an Agreement with Catalent to Manufacture AZD1222 for COVID-19

Shots:

  • Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Italy and prepare for large-scale commercial supply of AZD1222
  • The agreement ramps up the production of AZD1222 and will prepare the facility to enable round-the-clock manufacturing schedules and supply hundreds of millions of doses of AZD1222 from Aug’2020 to Mar’2022
  • The collaboration allows AstraZeneca to meet the global target of supplying 2B doses of its potential COVID-19 vaccine. Catalent’s 28,000 square-meter facility in Anagni offers extensive capabilities in aseptic liquid filling for biologics and sterile products across multiple vial sizes

Click here to read full press release/ article | Ref: Catalent | Image: Catalent

Related News: AstraZeneca To Supply 400M Doses of Vaccines to IVA by the End of 2020

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post